A transcriptomal profile for predicting complete cytogenetic response (CCR) in chronic phase CML patients treated with imatinib

被引：1
|
作者：
McWeeney, Shannon K. [1 ]
Pemberton, Lucy C. [2 ]
Harrington, Chris A. [1 ]
Druker, Brian J. [1 ]
Deminger, Michael W. [1 ]
机构：
[1] Oregon Hlth & Sci Univ, OHSU Canc Inst, Portland, OR USA
[2] Royal Victoria Infirm, Dept Haematol, Newcastle Upon Tyne, Tyne & Wear, England
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.1007.1007
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1007
引用
收藏
页码：305A / 305A
页数：1
相关论文
共 50 条
  • [1] Mechanisms of resistance to imatinib in chronic myeloid leukemia (CML) patients in chronic phase (CP) who achieved durable complete cytogenetic responses (CCR).
    Piazza, R
    Magistroni, V
    Tornaghi, L
    Andreoni, F
    Bungaro, S
    Cazzaniga, G
    Biondi, A
    Pogliani, E
    Varella-Garcia, M
    Corneo, G
    Gambacorti-Passerini, C
    BLOOD, 2003, 102 (11) : 319B - 319B
  • [2] BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML
    Press, RD
    Love, Z
    Tronnes, AA
    Yang, R
    Tran, T
    Mongoue-Tchokote, S
    Mori, M
    Mauro, MJ
    Deininger, MW
    Druker, BJ
    BLOOD, 2006, 107 (11) : 4250 - 4256
  • [3] The frequency of detection of BCR-ABL mutations in imatinib treated patients with chronic phase CML who attain a complete cytogenetic response (CCR) does not diminish with increasing duration of CCR but the associated loss of response is usually gradual
    Branford, S
    Rudzki, Z
    Grigg, A
    Seymour, J
    Browett, P
    Taylor, K
    Herrmann, R
    Schwarer, A
    Arthur, C
    Lynch, K
    Hughes, T
    BLOOD, 2004, 104 (11) : 81A - 81A
  • [4] The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years
    Piazza, Rocco G.
    Magistroni, Vera
    Franceschino, Anna
    Andreoni, Federica
    Tornaghi, Lucia
    Colnaghi, Federica
    Corneo, Gianmarco
    Pogliani, Enrico M.
    Gambacorti-Passerini, Carlo
    BLOOD CELLS MOLECULES AND DISEASES, 2006, 37 (02) : 111 - 115
  • [5] Factors predicting molecular and cytogenetic response in chronic myeloid leukemia patients treated with imatinib
    Roche-Lestienne, C
    Darré, S
    Laï, DL
    Facon, T
    Guilhot, J
    Preudhomme, C
    HAEMATOLOGICA, 2005, 90 (01) : 131 - 133
  • [6] Imatinib dose can be safely reduced after complete cytogenetic response (CCyR) in patients (pts) with chronic myeloid leukemia (CML) in early chronic phase (CP) treated with high-dose imatinib
    Jain, Nitin
    Kantarjian, Hagop M.
    Fava, Carmen
    Thomas, Deborah
    Burger, Jan A.
    Borthakur, Gautam
    Pate, Odeal
    Cortes, Jorge
    BLOOD, 2007, 110 (11) : 316A - 316A
  • [7] BCR-ABL RNA levels at the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib-treated chronic myeloid leukemia patients
    Press, RD
    Love, Z
    Tronnes, AA
    Kurilik, G
    Mauro, MJ
    Deininger, MW
    Druker, BJ
    BLOOD, 2004, 104 (11) : 312A - 312A
  • [8] A phase 3 pilot study of continuous imatinib versus pulsed imatinib with or without G-CSF in patients with chronic phase CML who have achieved a complete cytogenetic response to imatinib
    Heaney, Nicholas
    Drummond, Mark
    Kaeda, Jaspal
    Nicolini, Franck
    Clark, Richard
    Wilson, George
    Shepherd, Pat
    Tighe, Jane
    McLintock, Loma
    Hughes, Timothy
    Holyoake, Tessa L.
    BLOOD, 2007, 110 (11) : 313A - 313A
  • [9] Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate
    O'Dwyer, ME
    Mauro, MJ
    Blasdel, C
    Farnsworth, M
    Kurilik, G
    Hsieh, YC
    Mori, M
    Druker, BJ
    BLOOD, 2004, 103 (02) : 451 - 455
  • [10] Lack of cytogenetic response is an adverse prognostic factor for relapse of chronic phase CML patients treated with imatinib mesylate (STI571).
    O'Dwyer, M
    Mauro, MJ
    Blasdel, C
    Farnsworth, M
    Kurilik, G
    Fong, D
    Hsieh, YC
    Mori, M
    Capdeville, R
    Druker, BJ
    BLOOD, 2001, 98 (11) : 137A - 138A
12345